Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States; Department of Radiology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States; Department of Radiology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
J Control Release. 2017 Sep 10;261:23-30. doi: 10.1016/j.jconrel.2017.06.011. Epub 2017 Jun 15.
The development of nanomedicines presents the potential to deliver more potent drugs targeted more specifically to the site(s) of disease than is currently achievable. While encouraging results have been achieved, including at the clinical level, significant challenges and opportunities for development remain, both in terms of further developing the technology and in understanding the underlying biology. Given the lessons learned regarding variations in nanomedicine delivery to different tumor types and between different patients with the same tumor type, this is an area of drug development that, rather than simply benefiting from a patient-specific approach, actually demands it. The only way that this distribution information can be obtained is through imaging, and this requires labeling of the nanomedicine to enable detection outside the body. In this review, we describe recent advances in the labeling of nanomedicines, how imaging studies are guiding nanomedicine development, and the role of imaging in the future development of nanomedicines.
纳米医药的发展具有将更有效的药物靶向递送至疾病部位的潜力，比目前所能达到的效果更为精准。尽管已经取得了令人鼓舞的成果，包括在临床水平上，但是在进一步开发技术和理解基础生物学方面，仍然存在着重大的挑战和机遇。鉴于在不同肿瘤类型和同一肿瘤类型的不同患者中，纳米药物传递存在差异的教训，这是一个药物开发领域，它不仅需要采用个体化治疗方法，实际上还要求采用个体化治疗方法。获得这种分布信息的唯一方法是通过成像，这需要对纳米药物进行标记，以使其能够在体外被检测到。在这篇综述中，我们描述了纳米药物标记的最新进展，成像研究如何指导纳米药物的发展，以及成像在纳米药物未来发展中的作用。
